Parkinson’s disease biomarker: a patent evaluation of WO2013153386

Bibliography

• Hornykiewicz O. Basic research on dopamine in Parkinson’s disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis 2008;5(3-4):114-17
   Google Scholar
• Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J neural transm Suppl 2006(70):9-15
   Google Scholar
• Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat revNeurosci 2004;5(11):863-73
   Google Scholar
• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet neurol 2006;5(1):75-86
   PubMed Web of Science ®Google Scholar
• Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 2008;23(10):1428-34
   PubMed Web of Science ®Google Scholar
• Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med 2008;121(11 Suppl 2):S28-37
   PubMed Web of Science ®Google Scholar
• Poewe W, Gauthier S, Aarsland D, et al. Diagnosis and management of Parkinson’s disease dementia. Int J clin pract 2008;62(10):1581-7
   PubMed Web of Science ®Google Scholar
• Chen JJ. Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 2010;16(Suppl Implications):S87-93
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50(5):1346-50
   PubMed Web of Science ®Google Scholar
• Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat rev Genet 2006;7(4):306-18
   Google Scholar
• Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet neurol 2008;7(7):583-90
   PubMed Web of Science ®Google Scholar
• Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell 2013;155(6):1351-64
   PubMed Web of Science ®Google Scholar
• Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J biomed biotechnol 2012;2012:845618
   PubMedGoogle Scholar
• Przedborski S, Jackson-Lewis V, Naini AB, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001;76(5):1265-74
   PubMed Web of Science ®Google Scholar
• Lev N, Roncevic D, Ickowicz D, et al. Role of DJ-1 in Parkinson’s disease. J Mol Neurosci 2006;29(3):215-25
   Google Scholar
• Hyun CH, Yoon CY, Lee HJ, Lee SJ. LRRK2 as a potential genetic modifier of synucleinopathies: interlacing the two major genetic factors of Parkinson’s disease. Exp Neurobiol 2013;22(4):249-57
   Google Scholar
• Camilleri A, Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson’s disease. CNS Neurosci Ther 2014. [ Epub ahead of print]
   Google Scholar
• Pickrell AM, Fukui H, Wang X, et al. The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J neurosci 2011;31(27):9895-904
   Google Scholar
• Gautier CA, Corti O, Brice A. Mitochondrial dysfunctions in Parkinson’s disease. Rev Neurol (Paris) 2014;170(5):339-43
   PubMed Web of Science ®Google Scholar
• Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp neurol 2009;218(2):235-46
   PubMed Web of Science ®Google Scholar
• Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease. Curr opin neurobiol 2007;17(3):331-7
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 2008;131(Pt 2):389-96
   PubMed Web of Science ®Google Scholar
• Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56(3):336-41
   PubMed Web of Science ®Google Scholar
• Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010;8(1):e1000298
   PubMed Web of Science ®Google Scholar
• Jin SM, Lazarou M, Wang C, et al. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191(5):933-42
   Google Scholar
• Okatsu K, Oka T, Iguchi M, et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun 2012;3:1016
   PubMed Web of Science ®Google Scholar
• Lazarou M, Narendra DP, Jin SM, et al. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 2013;200(2):163-72
   PubMed Web of Science ®Google Scholar
• McLelland GL, Soubannier V, Chen CX, et al. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 2014;33(4):282-95
   PubMed Web of Science ®Google Scholar
• Kazlauskaite A, Kondapalli C, Gourlay R, et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J 2014;460(1):127-39
   PubMed Web of Science ®Google Scholar
• Kazlauskaite A, Kelly V, Johnson C, et al. Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity. Open biol 2014;4:130213
   PubMed Web of Science ®Google Scholar
• Narendra D, Walker JE, Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb Perspect Biology 2012;4:11
   Google Scholar
• Shiba-Fukushima K, Imai Y, Yoshida S, et al. PINK1-mediated phosporylation of the Parkin ubiquitin-like primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep 2012;2:1002
   PubMed Web of Science ®Google Scholar
• Meissner C, Lorenz H, Weihofen A, et al. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J neurochem 2011;117(5):856-67
   PubMed Web of Science ®Google Scholar
• Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid redox signal 2011;14(10):1929-38
   PubMed Web of Science ®Google Scholar
• Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013;136(Pt 8):2419-31
   PubMed Web of Science ®Google Scholar
• Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat med 2010;16(11):1223-6
   PubMed Web of Science ®Google Scholar
• Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson’s disease. Parkinsonism relat disord 2014;20(Suppl 1):S132-6
   PubMedGoogle Scholar
• Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr med chem 2013;20(13):1662-72
   PubMed Web of Science ®Google Scholar
• Amadoro G, Corsetti V, Florenzano F, et al. Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink-parkin pathway. Front aging neurosci 2014;6:18
   PubMed Web of Science ®Google Scholar